Santarelli P, Biscione F, Natale A, Manzoli A, Lanza G A
Institute of Cardiology, Catholic University, Rome, Italy.
Cardiovasc Drugs Ther. 1994 Aug;8(4):653-8. doi: 10.1007/BF00877419.
This study compares the electrophysiologic effects of amlodipine and diltiazem in patients with coronary artery disease concomitantly treated with background beta-blocking therapy. Thirty patients were included in an open-label parallel study in two phases. During phase 1, patients were screened and placed on maintenance atenolol therapy at 50 or 100 mg/day, while phase 2 consisted of right-sided catheterization and randomization of patients to either amlodipine (10 mg i.v.) or diltiazem (10 mg i.v.). Following treatment with amlodipine, no significant alteration in markers of electrophysiological activity was observed. Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0.04), AH interval (p < 0.02), and Wenckebach CL (WCL, p < 0.001), and a trend towards an increase in sinus node recovery time (SNRT, p = 0.057). No effects were observed with regard to HV interval and corrected SNRT. The results of this study indicate that 10 mg intravenous amlodipine has no significant electrophysiological action on sinus or AV node function in patients receiving beta-blocker therapy with atenolol, suggesting that amlodipine can be added to beta-blockers to treat patients with myocardial ischemia and/or hypertension without any significant increase in the risk of bradyarrhythmias.
本研究比较了氨氯地平和地尔硫䓬在接受背景β受体阻滞剂治疗的冠心病患者中的电生理效应。30名患者纳入一项开放标签的两阶段平行研究。在第1阶段,对患者进行筛查并给予阿替洛尔维持治疗,剂量为50或100毫克/天,而第2阶段包括右侧心导管检查,并将患者随机分为接受氨氯地平(静脉注射10毫克)或地尔硫䓬(静脉注射10毫克)治疗。给予氨氯地平治疗后,未观察到电生理活动标志物有明显改变。地尔硫䓬治疗导致窦性周期长度(SCL,p<0.04)、AH间期(p<0.02)和文氏周期长度(WCL,p<0.001)显著延长,且窦性结恢复时间(SNRT,p=0.057)有增加趋势。未观察到对HV间期和校正SNRT有影响。本研究结果表明,10毫克静脉注射氨氯地平对接受阿替洛尔β受体阻滞剂治疗的患者的窦房结或房室结功能无显著电生理作用,提示氨氯地平可添加到β受体阻滞剂中,用于治疗心肌缺血和/或高血压患者,而不会显著增加缓慢性心律失常的风险。